Global Head Oncology Early Clinical Development
Vasileios Askoxylakis is the Global Head of Oncology Early Clinical Development at Servier Pharmaceuticals. He is a radiation oncologist and physician scientist with more than 15 years of oncology translational research, radiation oncology and oncology drug development experience in both academia and the pharmaceutical industry.
Vasileios comes to Servier from Novartis Institutes for BioMedical Research, where he spent the last 4 years in the Translational Clinical Oncology group leading new therapies from the candidate selection phase into early clinical development and through clinical proof-of-concept. His work included translational and early phase clinical trials for novel therapeutics across multiple platforms, including small molecule targeted therapies, immunotherapies, antibody-drug-conjugates and radioligand therapies. Earlier in his career, he led early- and mid-stage clinical development of targeted nanotherapeutics and bi-specific antibodies at Merrimack Pharmaceuticals.
Vasileios earned his MD/PhD degree from the Heidelberg University School of Medicine in Germany. Following a postdoctoral research fellowship with focus on molecular targeting and peptide-based radionuclide therapy at the German Cancer Research Center (DKFZ), he completed his training in radiation oncology at the University Hospital Heidelberg. He continued his academic career working as a translational scientist at Massachusetts General Hospital/Harvard Medical School.